Regulator of mRNA, miRNA and siRNA
The amount of mRNA is determined by the balance between its transcription rate from DNA and its degradation rate by RNases.
Does the quantity of mRNA perfectly correspond to the amount of protein? Not exactly. The translation of mRNA into protein can be inhibited by very short RNA molecules, such as microRNA (miRNA) and small interfering RNA (siRNA). These regulatory RNAs bind to target mRNA and suppress its translation or promote its degradation, thereby influencing protein production.
What are the differences between miRNA and siRNA? Their mechanisms are quite similar. Both involve specific RNA molecules binding to mRNA, preventing RNA transcriptase from functioning properly. For example, imagine a railway track designed for train wheels; if the track becomes too thick in certain areas, the train will derail instead of following the path smoothly.
miRNA is primarily endogenous, meaning it is naturally produced within cells. It does not perfectly match the target mRNA but binds with slight mismatches in the base sequence. Additionally, miRNA has a broader range of targets, acting somewhat like a grenade, where its inhibitory strength can vary depending on the type of RNA it binds to. On the other hand, siRNA matches the target mRNA perfectly. While it can be naturally produced within cells, it is most commonly synthesized in laboratories and introduced into cells to inhibit specific genes for experimental purposes. Unlike miRNA, siRNA functions like a sniper rifle, precisely targeting and silencing a single gene with high specificity.

Research of miRNA for Diagnosis
This miRNA was a significant topic that won the Nobel Prize in 2024, highlighting its profound importance. However, studying miRNA manually, gene by gene, is not feasible for human eyes and hands alone. Therefore, this field heavily relies on computational programs for research. The ability to process big data is crucial in this context, and it plays a pivotal role in bioinformatics, driving advancements in the field of life sciences. One example is the critical role miRNA plays in the development of brain cells. By measuring the concentration of specific miRNAs, it is possible to assess the normality of a fetus’s brain. For instance, miR-210 and miR-374a are notable examples. These two miRNAs are particularly useful in evaluating the hypoxic conditions in a fetus’s brain, providing valuable insights into fetal brain health.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5853646
Limitation of miRNA and it’s future
If we have a precise map of miRNAs, we could identify which miRNAs are deficient in individuals and supplement them accordingly or determine which miRNAs are effective for specific diseases. This could enable disease treatments that are far more specific than chemical-based drugs. Indeed, there have been various attempts to develop drugs using this concept. However, as previously mentioned, miRNAs function like “grenades,” leading to unexpected toxicity in many cases.
On the other hand, siRNA-based approaches, which operate more like “sniper rifles,” have seen greater success, with about six siRNA-based drugs approved by the FDA. In contrast, miRNA-based therapies have been progressing slowly. Challenges remain in delivering miRNAs to precise target cells, managing unexpected cellular toxicity, and evaluating their stability.
https://www.nature.com/articles/s41587-024-02480-0
According to a paper published in November 2024, some miRNA-based drugs have reached phase 1 or phase 2 clinical trials, but many fail toxicity tests. Recently, the focus has shifted more toward diagnostics. It seems miRNA is being prioritized for diagnostic applications, while siRNA is advancing in the therapeutic field. Understanding miRNA as a tool for diagnosis and siRNA as the therapeutic counterpart provides a clear picture of current trends.